Phreesia (NYSE:PHR – Free Report) had its price target raised by JPMorgan Chase & Co. from $27.00 to $28.00 in a research report sent to investors on Monday, Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock.
PHR has been the topic of several other research reports. JMP Securities reaffirmed a market outperform rating and issued a $30.00 price target on shares of Phreesia in a research report on Thursday, September 5th. KeyCorp cut their target price on Phreesia from $27.00 to $25.00 and set an overweight rating on the stock in a research report on Thursday, July 11th. Robert W. Baird raised their price objective on Phreesia from $31.00 to $34.00 and gave the company an outperform rating in a research note on Friday, September 6th. DA Davidson reiterated a buy rating and issued a $32.00 target price on shares of Phreesia in a research note on Thursday, September 5th. Finally, Needham & Company LLC reiterated a buy rating and issued a $29.00 target price on shares of Phreesia in a report on Thursday, September 5th. One analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat, Phreesia currently has a consensus rating of Moderate Buy and a consensus price target of $29.42.
Phreesia Stock Performance
Insider Transactions at Phreesia
In related news, General Counsel Allison C. Hoffman sold 14,110 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $26.03, for a total value of $367,283.30. Following the transaction, the general counsel now owns 121,003 shares in the company, valued at $3,149,708.09. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In other Phreesia news, General Counsel Allison C. Hoffman sold 14,110 shares of the company’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $26.03, for a total transaction of $367,283.30. Following the sale, the general counsel now directly owns 121,003 shares of the company’s stock, valued at $3,149,708.09. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, General Counsel Allison C. Hoffman sold 2,622 shares of Phreesia stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $23.25, for a total transaction of $60,961.50. Following the completion of the transaction, the general counsel now owns 123,075 shares of the company’s stock, valued at approximately $2,861,493.75. The disclosure for this sale can be found here. Insiders sold a total of 46,364 shares of company stock worth $1,132,627 in the last quarter. Insiders own 5.80% of the company’s stock.
Institutional Investors Weigh In On Phreesia
Several institutional investors have recently made changes to their positions in PHR. Vanguard Group Inc. raised its stake in shares of Phreesia by 4.4% during the 4th quarter. Vanguard Group Inc. now owns 4,628,441 shares of the company’s stock valued at $107,148,000 after purchasing an additional 194,035 shares during the period. Champlain Investment Partners LLC bought a new stake in Phreesia during the first quarter valued at $29,941,000. Brown Advisory Inc. grew its position in Phreesia by 22.2% during the fourth quarter. Brown Advisory Inc. now owns 3,950,356 shares of the company’s stock worth $91,451,000 after buying an additional 716,374 shares in the last quarter. Boston Partners bought a new position in Phreesia in the 1st quarter worth about $669,000. Finally, Blair William & Co. IL raised its holdings in shares of Phreesia by 42.6% in the 1st quarter. Blair William & Co. IL now owns 752,700 shares of the company’s stock valued at $18,012,000 after acquiring an additional 224,950 shares in the last quarter. Hedge funds and other institutional investors own 92.10% of the company’s stock.
About Phreesia
Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.
Further Reading
- Five stocks we like better than Phreesia
- There Are Different Types of Stock To Invest In
- 3 Leveraged ETFs to Multiply Returns
- The Role Economic Reports Play in a Successful Investment Strategy
- A Tale of Two Titans: Unveiling the Value in Baidu and JD.com
- Quiet Period Expirations Explained
- Is the AI-Capable iPhone 16 the Start of a Sales Super-Cycle?
Receive News & Ratings for Phreesia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phreesia and related companies with MarketBeat.com's FREE daily email newsletter.